For adult patients with moderately to severely active ulcerative colitis (UC) or Crohn’s disease when other therapies have not worked well enough or cannot be tolerated.
Insurance coverage
Use our formulary lookup tool to find ENTYVIO insurance coverage information for patients in your area.
Please enter either a ZIP Code or HCP NPI.
Prior authorization may be required. For full policy details, please visit health plan website.
Unrestricted refers to coverage that does not require biologic step-edits. Restricted refers to coverage that requires step therapy with one or more biologics. Data regarding current unrestricted commercial coverage for ENTYVIO as of July 2023 are derived from Managed Markets Insights & Technology (MMIT). September 2023.
Not Covered=ENTYVIO is not reimbursed.
*Top plans are based on prescription volume in specified area.
IMPORTANT SAFETY INFORMATION
Contraindications
WARNINGS AND PRECAUTIONS
IMPORTANT SAFETY INFORMATION
Contraindications
ENTYVIO is contraindicated in patients who have had a known serious or severe hypersensitivity reaction to ENTYVIO or any of its excipients.
Warnings and precautions
Adverse reactions
The most common adverse reactions (incidence ≥3% and ≥1% higher than placebo) were: nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, pain in extremities, and injection site reactions with subcutaneous administration.
Drug interactions
Because of the potential for increased risk of PML and other infections, avoid the concomitant use of ENTYVIO with natalizumab products and with TNF blockers.
INDICATIONS
Adult Ulcerative Colitis (UC):
ENTYVIO is indicated in adults for the treatment of moderately to severely active UC.
Adult Crohn’s Disease (CD):
ENTYVIO is indicated in adults for the treatment of moderately to severely active CD.
Dosage forms & strengths:
Please click for Full Prescribing Information.